ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$8.11
0.51 (6.71%)
▲
5d:
+21.77%
30d:
+32.3%
90d:
+131.05%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.7/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ABCL this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ABCL is 15.9% above its trading range ($7.00). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ABCL is 15.9% above its trading range ($7.00). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $8.11, which is considered extended relative to its 30-day fair value range of $5.13 to $7.00.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $5.33, while resistance sits at $8.42. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: ABCL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.43 (+28.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $5.33, while resistance sits at $8.42. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: ABCL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.43 (+28.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.13 -
$7.00
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+15.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.7%)
- BULLISH: Trading 28.6% below Wall St target ($10.43)
- WARNING: Recommendation downgraded due to 15.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$5.13 -
$7.00
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.33
Resistance Level
$8.42
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.26
Wall Street Target
$10.43
(+28.6%)
Revenue Growth (YoY)
96.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-181.7%
Share & Embed Analysis
Last updated: July 03, 2026 5:55 PM ET
Data refreshes hourly during market hours. Next update: 6:55 PM
Data refreshes hourly during market hours. Next update: 6:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
